Publications

Metrics

Google ScholarScopusUCL IrisORCiD

Book chapters 6
Journal articles 74
Total citations 7371
h-index 39
i10-index 64

Last updated October 2019

Book chapters

  1. Biofluid Biomarkers for Huntington’s Disease
    F Rodrigues, L Byrne & E Wild
    In Methods in Molecular Biology: Huntington’s Disease
    eds. Precious, Rosser & Dunnett. Springer, 2018.
  2. Premanifest and Early Huntington’s Disease
    E Wild & S Tabrizi.
    In Huntington’s Disease (Oxford Monographs on Medical Genetics), 3rd ed. Eds G Bates, L Jones & S Tabrizi. Oxford University Press, 2015.
  3. Huntington’s Disease & Other Choreas
    S Haider, E Wild & S Tabrizi.
    In Neurodegeneration, ed. A Schapira. Wiley, 2014.
  4. Huntington’s disease look-alike syndromes
    E Wild & S Tabrizi.
    In Oxford Textbooks in Clinical Neurology: Movement Disorders (2nd edition), ed. D Burn. Oxford University Press, 2013.
  5. Huntington’s Disease
    S Tabrizi & E Wild
    In Neurogenetics: A Guide for Clinicians (2nd edition), ed. N Wood. Cambridge University Press, 2012
  6. Huntington’s Disease and Dementia
    E Wild, N Hobbs & S Henley.
    In Neuroimaging in Dementia (1st edition), ed. F Barkhof, J Valk & N Fox. Springer-Verlag, 2011

PhD Thesis

Identification and evaluation of biomarkers for Huntington’s disease, 2009. University College London.

Peer-reviewed journal articles


  1. Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington’s disease Young Adult Study (HD-YAS): a cross-sectional analysis.
    Lancet Neurol (2020) 19, 502-512.
    Scahill, R. I., Zeun, P., Osborne-Crowley, K., Johnson, E. B., Gregory, S., Parker, C., Lowe, J., Nair, A., O’Callaghan, C., Langley, C., Papoutsi, M., McColgan, P., Estevez-Fraga, C., Fayer, K., Wellington, H., Rodrigues, F. B., Byrne, L. M., Heselgrave, A., Hyare, H., Sampaio, C., Zetterberg, H., Zhang, H., Wild, E. J., Rees, G., Robbins, T. W., Sahakian, B. J., Langbehn, D. and Tabrizi, S. J.
  2. Huntington’s Disease Clinical Trials Corner: April 2020.
    J Huntingtons Dis (2020) 9, 185-197.
    Rodrigues, F. B. and Wild, E. J.
  3. Characterizing White Matter in Huntington’s Disease.
    Mov Disord Clin Pract (2020) 7, 52-60.
    Gregory, S., Johnson, E., Byrne, L. M., Rodrigues, F. B., Henderson, A., Moss, J., Thomas, D., Zhang, H., De Vita, E., Tabrizi, S. J., Rees, G., Scahill, R. I. and Wild, E. J.
  4. Fluid and imaging biomarkers for Huntington’s disease.
    Mol Cell Neurosci (2019) 97, 67-80.
    Zeun, P., Scahill, R. I., Tabrizi, S. J. and Wild, E. J.
  5. One decade ago, one decade ahead in huntington’s disease.
    Mov Disord (2019) 34, 1434-1439.
    Wild, E. J. and Tabrizi, S. J.
  6. Targeting Huntingtin Expression in Patients with Huntington’s Disease.
    N Engl J Med (2019) 380, 2307-2316.
    Tabrizi, S. J., Leavitt, B. R., Landwehrmeyer, G. B., Wild, E. J., Saft, C., Barker, R. A., Blair, N. F., Craufurd, D., Priller, J., Rickards, H., Rosser, A., Kordasiewicz, H. B., Czech, C., Swayze, E. E., Norris, D. A., Baumann, T., Gerlach, I., Schobel, S. A., Paz, E., Smith, A. V., Bennett, C. F., Lane, R. M. and Phase 1-2a, I.-H. S. S. T.
  7. Huntington’s Disease Clinical Trials Corner: January 2019.
    J Huntingtons Dis (2019) 8, 115-125.
    Rodrigues, F. B., Quinn, L. and Wild, E. J.
  8. Huntington’s Disease Clinical Trials Corner: June 2019.
    J Huntingtons Dis (2019) 8, 363-371.
    Rodrigues, F. B., Ferreira, J. J. and Wild, E. J.
  9. Cerebrospinal fluid flow dynamics in Huntington’s disease evaluated by phase contrast MRI.
    Eur J Neurosci (2019) 49, 1632-1639.
    Rodrigues, F. B., Byrne, L. M., De Vita, E., Johnson, E. B., Hobbs, N. Z., Thornton, J. S., Scahill, R. I. and Wild, E. J.
  10. Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.
    JAMA Neurol (2019).
    Bridel, C., van Wieringen, W. N., Zetterberg, H., Tijms, B. M., Teunissen, C. E., and the, N. F. L. G., Alvarez-Cermeno, J. C., Andreasson, U., Axelsson, M., Backstrom, D. C., Bartos, A., Bjerke, M., Blennow, K., Boxer, A., Brundin, L., Burman, J., Christensen, T., Fialova, L., Forsgren, L., Frederiksen, J. L., Gisslen, M., Gray, E., Gunnarsson, M., Hall, S., Hansson, O., Herbert, M. K., Jakobsson, J., Jessen-Krut, J., Janelidze, S., Johannsson, G., Jonsson, M., Kappos, L., Khademi, M., Khalil, M., Kuhle, J., Landen, M., Leinonen, V., Logroscino, G., Lu, C. H., Lycke, J., Magdalinou, N. K., Malaspina, A., Mattsson, N., Meeter, L. H., Mehta, S. R., Modvig, S., Olsson, T., Paterson, R. W., Perez-Santiago, J., Piehl, F., Pijnenburg, Y. A. L., Pyykko, O. T., Ragnarsson, O., Rojas, J. C., Romme Christensen, J., Sandberg, L., Scherling, C. S., Schott, J. M., Sellebjerg, F. T., Simone, I. L., Skillback, T., Stilund, M., Sundstrom, P., Svenningsson, A., Tortelli, R., Tortorella, C., Trentini, A., Troiano, M., Turner, M. R., van Swieten, J. C., Vagberg, M., Verbeek, M. M., Villar, L. M., Visser, P. J., Wallin, A., Weiss, A., Wikkelso, C. and Wild, E. J.
  11. Comparison of the Huntington’s Disease like 2 and Huntington’s Disease Clinical Phenotypes.
    Mov Disord Clin Pract (2019) 6, 302-311.
    Anderson, D. G., Ferreira-Correia, A., Rodrigues, F. B., Aziz, N. A., Carr, J., Wild, E. J., Margolis, R. L. and Krause, A.
  12. Huntington’s Disease Clinical Trials Corner: February 2018.
    J Huntingtons Dis (2018) 7, 89-98.
    Rodrigues, F. B. and Wild, E. J.
  13. Huntington’s Disease Clinical Trials Corner: August 2018.
    J Huntingtons Dis (2018) 7, 279-286.
    Rodrigues, F. B. and Wild, E. J.
  14. Physician perception versus true efficacy of tetrabenazine for Huntington’s disease.
    Curr Med Res Opin (2018) 34, 1537-1538.
    Rodrigues, F. B., Ferreira, J. J. and Wild, E. J.
  15. Biofluid Biomarkers in Huntington’s Disease.
    Methods Mol Biol (2018) 1780, 329-396.
    Rodrigues, F. B., Byrne, L. M. and Wild, E. J.
  16. Predictors for a dementia gene mutation based on gene-panel next-generation sequencing of a large dementia referral series.
    Mol Psychiatry (2018).
    Koriath, C., Kenny, J., Adamson, G., Druyeh, R., Taylor, W., Beck, J., Quinn, L., Mok, T. H., Dimitriadis, A., Norsworthy, P., Bass, N., Carter, J., Walker, Z., Kipps, C., Coulthard, E., Polke, J. M., Bernal-Quiros, M., Denning, N., Thomas, R., Raybould, R., Williams, J., Mummery, C. J., Wild, E. J., Houlden, H., Tabrizi, S. J., Rossor, M. N., Hummerich, H., Warren, J. D., Rowe, J. B., Rohrer, J. D., Schott, J. M., Fox, N. C., Collinge, J. and Mead, S.
  17. Neurofilament light protein in blood predicts regional atrophy in Huntington disease.
    Neurology (2018) 90, e717-e723.
    Johnson, E. B., Byrne, L. M., Gregory, S., Rodrigues, F. B., Blennow, K., Durr, A., Leavitt, B. R., Roos, R. A., Zetterberg, H., Tabrizi, S. J., Scahill, R. I., Wild, E. J. and Group, T.-H. S.
  18. Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington’s disease.
    Sci Transl Med (2018) 10.
    Byrne, L. M., Rodrigues, F. B., Johnson, E. B., Wijeratne, P. A., De Vita, E., Alexander, D. C., Palermo, G., Czech, C., Schobel, S., Scahill, R. I., Heslegrave, A., Zetterberg, H. and Wild, E. J.
  19. Cerebrospinal fluid neurogranin and TREM2 in Huntington’s disease.
    Sci Rep (2018) 8, 4260.
    Byrne, L. M., Rodrigues, F. B., Johnson, E. B., De Vita, E., Blennow, K., Scahill, R., Zetterberg, H., Heslegrave, A. and Wild, E. J.
  20. Perinatal insults and neurodevelopmental disorders may impact Huntington’s disease age of diagnosis.
    Parkinsonism Relat Disord (2018) 55, 55-60.
    Barkhuizen, M., Rodrigues, F. B., Anderson, D. G., Winkens, B., Network, R. I. o. t. E. H. s. D., Wild, E. J., Kramer, B. W. and Gavilanes, A. W. D.
  21. Therapies targeting DNA and RNA in Huntington’s disease.
    Lancet Neurol (2017) 16, 837-847.
    Wild, E. J. and Tabrizi, S. J.
  22. Neurofilament light protein in CSF and blood is associated with neurodegeneration and disease severity in Huntington’s disease R6/2 mice.
    Sci Rep (2017) 7, 14114.
    Soylu-Kucharz, R., Sandelius, A., Sjogren, M., Blennow, K., Wild, E. J., Zetterberg, H. and Bjorkqvist, M.
  23. Ghost Pills: A Case Report.
    Ann Intern Med (2017) 166, 609.
    Salanio, D. M., Taylor, R., Stanton, J. E. D. and Wild, E. J.
  24. Clinical Trials Corner: September 2017.
    J Huntingtons Dis (2017) 6, 255-263.
    Rodrigues, F. B. and Wild, E. J.
  25. Tetrabenazine Versus Deutetrabenazine for Huntington’s Disease: Twins or Distant Cousins?
    Mov Disord Clin Pract (2017) 4, 582-585.
    Rodrigues, F. B., Duarte, G. S., Costa, J., Ferreira, J. J. and Wild, E. J.
  26. Meta-research metrics matter: letter regarding article “indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease”.
    J Clin Mov Disord (2017) 4, 19.
    Rodrigues, F. B., Duarte, G. S., Costa, J., Ferreira, J. J. and Wild, E. J.
  27. Quantification of huntingtin protein species in Huntington’s disease patient leukocytes using optimised electrochemiluminescence immunoassays.
    PLoS One (2017) 12, e0189891.
    Hensman Moss, D. J., Robertson, N., Farmer, R., Scahill, R. I., Haider, S., Tessari, M. A., Flynn, G., Fischer, D. F., Wild, E. J., Macdonald, D. and Tabrizi, S. J.
  28. Validation of Ultrasensitive Mutant Huntingtin Detection in Human Cerebrospinal Fluid by Single Molecule Counting Immunoassay.
    J Huntingtons Dis (2017) 6, 349-361.
    Fodale, V., Boggio, R., Daldin, M., Cariulo, C., Spiezia, M. C., Byrne, L. M., Leavitt, B. R., Wild, E. J., Macdonald, D., Weiss, A. and Bresciani, A.
  29. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington’s disease: a retrospective cohort analysis.
    Lancet Neurol (2017) 16, 601-609.
    Byrne, L. M., Rodrigues, F. B., Blennow, K., Durr, A., Leavitt, B. R., Roos, R. A. C., Scahill, R. I., Tabrizi, S. J., Zetterberg, H., Langbehn, D. and Wild, E. J.
  30. Huntington’s Disease: The Most Curable Incurable Brain Disorder?
    EBioMedicine (2016) 8, 3-4.
    Wild, E. J.
  31. George Huntington: a legacy of inquiry, empathy and hope.
    Brain (2016) 139, 2326-2333.
    Wexler, A., Wild, E. J. and Tabrizi, S. J.
  32. Psychogenic non-epileptic seizures in early Huntington’s disease.
    Pract Neurol (2016) 16, 452-454.
    Rodrigues, F. B. and Wild, E. J.
  33. Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington’s Disease.
    PLoS One (2016) 11, e0163479.
    Rodrigues, F. B., Byrne, L. M., McColgan, P., Robertson, N., Tabrizi, S. J., Zetterberg, H. and Wild, E. J.
  34. Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington’s disease.
    J Neurochem (2016) 139, 22-25.
    Rodrigues, F. B., Byrne, L., McColgan, P., Robertson, N., Tabrizi, S. J., Leavitt, B. R., Zetterberg, H. and Wild, E. J.
  35. Cerebrospinal Fluid Biomarkers for Huntington’s Disease.
    J Huntingtons Dis (2016) 5, 1-13.
    Byrne, L. M. and Wild, E. J.
  36. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington’s disease patients.
    J Clin Invest (2015) 125, 1979-1986.
    Wild, E. J., Boggio, R., Langbehn, D., Robertson, N., Haider, S., Miller, J. R., Zetterberg, H., Leavitt, B. R., Kuhn, R., Tabrizi, S. J., Macdonald, D. and Weiss, A.
  37. Huntington disease.
    Nat Rev Dis Primers (2015) 1, 15005.
    Bates, G. P., Dorsey, R., Gusella, J. F., Hayden, M. R., Kay, C., Leavitt, B. R., Nance, M., Ross, C. A., Scahill, R. I., Wetzel, R., Wild, E. J. and Tabrizi, S. J.
  38. Targets for future clinical trials in Huntington’s disease: what’s in the pipeline?
    Mov Disord (2014) 29, 1434-1445.
    Wild, E. J. and Tabrizi, S. J.
  39. Huntington disease: natural history, biomarkers and prospects for therapeutics.
    Nat Rev Neurol (2014) 10, 204-216.
    Ross, C. A., Aylward, E. H., Wild, E. J., Langbehn, D. R., Long, J. D., Warner, J. H., Scahill, R. I., Leavitt, B. R., Stout, J. C., Paulsen, J. S., Reilmann, R., Unschuld, P. G., Wexler, A., Margolis, R. L. and Tabrizi, S. J.
  40. C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies.
    Neurology (2014) 82, 292-299.
    Hensman Moss, D. J., Poulter, M., Beck, J., Hehir, J., Polke, J. M., Campbell, T., Adamson, G., Mudanohwo, E., McColgan, P., Haworth, A., Wild, E. J., Sweeney, M. G., Houlden, H., Mead, S. and Tabrizi, S. J.
  41. JAK/STAT Signalling in Huntington’s Disease Immune Cells.
    PLoS Curr (2013) 5.
    Trager, U., Magnusson, A., Lahiri Swales, N., Wild, E., North, J., Lowdell, M. and Bjorkqvist, M.
  42. HDBuzz: empowering patients through accessible education.
    Trends Mol Med (2012) 18, 1-3.
    Wild, E. J. and Carroll, J. B.
  43. Mutant huntingtin fragmentation in immune cells tracks Huntington’s disease progression.
    J Clin Invest (2012) 122, 3731-3736.
    Weiss, A., Trager, U., Wild, E. J., Grueninger, S., Farmer, R., Landles, C., Scahill, R. I., Lahiri, N., Haider, S., Macdonald, D., Frost, C., Bates, G. P., Bilbe, G., Kuhn, R., Andre, R. and Tabrizi, S. J.
  44. Biomarkers for Huntington’s disease: an update.
    Expert Opin Med Diagn (2012) 6, 371-375.
    Scahill, R. I., Wild, E. J. and Tabrizi, S. J.
  45. Huntington’s disease: fighting on many fronts.
    Brain (2012) 135, 998-1001.
    Andre, R., Wild, E. J. and Tabrizi, S. J.
  46. Brain-derived neurotrophic factor in patients with Huntington’s disease.
    PLoS One (2011) 6, e22966.
    Zuccato, C., Marullo, M., Vitali, B., Tarditi, A., Mariotti, C., Valenza, M., Lahiri, N., Wild, E. J., Sassone, J., Ciammola, A., Bachoud-Levi, A. C., Tabrizi, S. J., Di Donato, S. and Cattaneo, E.
  47. Abnormal peripheral chemokine profile in Huntington’s disease.
    PLoS Curr (2011) 3, RRN1231.
    Wild, E., Magnusson, A., Lahiri, N., Krus, U., Orth, M., Tabrizi, S. J. and Bjorkqvist, M.
  48. Observing Huntington’s disease: the European Huntington’s Disease Network’s REGISTRY.
    J Neurol Neurosurg Psychiatry (2011) 82, 1409-1412.
    Orth, M., European Huntington’s Disease, N., Handley, O. J., Schwenke, C., Dunnett, S., Wild, E. J., Tabrizi, S. J. and Landwehrmeyer, G. B.
  49. Mutant huntingtin causes defective actin remodeling during stress: defining a new role for transglutaminase 2 in neurodegenerative disease.
    Hum Mol Genet (2011) 20, 1937-1951.
    Munsie, L., Caron, N., Atwal, R. S., Marsden, I., Wild, E. J., Bamburg, J. R., Tabrizi, S. J. and Truant, R.
  50. Rate and acceleration of whole-brain atrophy in premanifest and early Huntington’s disease.
    Mov Disord (2010) 25, 888-895.
    Wild, E. J., Henley, S. M., Hobbs, N. Z., Frost, C., MacManus, D. G., Barker, R. A., Fox, N. C. and Tabrizi, S. J.
  51. Observing Huntington’s Disease: the European Huntington’s Disease Network’s REGISTRY.
    PLoS Curr (2010) 2, RRN1184.
    Orth, M., Handley, O. J., Schwenke, C., Dunnett, S. B., Craufurd, D., Ho, A. K., Wild, E., Tabrizi, S. J., Landwehrmeyer, G. B. and Investigators of the European Huntington’s Disease, N.
  52. The progression of regional atrophy in premanifest and early Huntington’s disease: a longitudinal voxel-based morphometry study.
    J Neurol Neurosurg Psychiatry (2010) 81, 756-763.
    Hobbs, N. Z., Henley, S. M., Ridgway, G. R., Wild, E. J., Barker, R. A., Scahill, R. I., Barnes, J., Fox, N. C. and Tabrizi, S. J.
  53. Onset and progression of pathologic atrophy in Huntington disease: a longitudinal MR imaging study.
    AJNR Am J Neuroradiol (2010) 31, 1036-1041.
    Hobbs, N. Z., Barnes, J., Frost, C., Henley, S. M., Wild, E. J., Macdonald, K., Barker, R. A., Scahill, R. I., Fox, N. C. and Tabrizi, S. J.
  54. Serial volumetric MRI in Parkinsonian disorders.
    Mov Disord (2009) 24 Suppl 2, S691-698.
    Wild, E. J. and Fox, N. C.
  55. Automated quantification of caudate atrophy by local registration of serial MRI: evaluation and application in Huntington’s disease.
    Neuroimage (2009) 47, 1659-1665.
    Hobbs, N. Z., Henley, S. M., Wild, E. J., Leung, K. K., Frost, C., Barker, R. A., Scahill, R. I., Barnes, J., Tabrizi, S. J. and Fox, N. C.
  56. Relationship between CAG repeat length and brain volume in premanifest and early Huntington’s disease.
    J Neurol (2009) 256, 203-212.
    Henley, S. M., Wild, E. J., Hobbs, N. Z., Scahill, R. I., Ridgway, G. R., Macmanus, D. G., Barker, R. A., Fox, N. C. and Tabrizi, S. J.
  57. Whole-brain atrophy as a measure of progression in premanifest and early Huntington’s disease.
    Mov Disord (2009) 24, 932-936.
    Henley, S. M., Wild, E. J., Hobbs, N. Z., Frost, C., MacManus, D. G., Barker, R. A., Fox, N. C. and Tabrizi, S. J.
  58. Harnessing immune alterations in neurodegenerative diseases.
    Neuron (2009) 64, 21-24.
    Bjorkqvist, M., Wild, E. J. and Tabrizi, S. J.
  59. Biomarkers for Huntington’s disease.
    Expert Opin Med Diagn (2008) 2, 47-62.
    Wild, E. J. and Tabrizi, S. J.
  60. Huntington’s disease phenocopies are clinically and genetically heterogeneous.
    Mov Disord (2008) 23, 716-720.
    Wild, E. J., Mudanohwo, E. E., Sweeney, M. G., Schneider, S. A., Beck, J., Bhatia, K. P., Rossor, M. N., Davis, M. B. and Tabrizi, S. J.
  61. Immune markers for Huntington’s disease?
    Expert Rev Neurother (2008) 8, 1779-1781.
    Wild, E., Bjorkqvist, M. and Tabrizi, S. J.
  62. Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington’s disease.
    Brain (2008) 131, 2851-2859.
    Leoni, V., Mariotti, C., Tabrizi, S. J., Valenza, M., Wild, E. J., Henley, S. M., Hobbs, N. Z., Mandelli, M. L., Grisoli, M., Bjorkhem, I., Cattaneo, E. and Di Donato, S.
  63. Defective emotion recognition in early HD is neuropsychologically and anatomically generic.
    Neuropsychologia (2008) 46, 2152-2160.
    Henley, S. M., Wild, E. J., Hobbs, N. Z., Warren, J. D., Frost, C., Scahill, R. I., Ridgway, G. R., MacManus, D. G., Barker, R. A., Fox, N. C. and Tabrizi, S. J.
  64. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington’s disease.
    J Exp Med (2008) 205, 1869-1877.
    Bjorkqvist, M., Wild, E. J., Thiele, J., Silvestroni, A., Andre, R., Lahiri, N., Raibon, E., Lee, R. V., Benn, C. L., Soulet, D., Magnusson, A., Woodman, B., Landles, C., Pouladi, M. A., Hayden, M. R., Khalili-Shirazi, A., Lowdell, M. W., Brundin, P., Bates, G. P., Leavitt, B. R., Moller, T. and Tabrizi, S. J.
  65. Rapid eye movement sleep disturbances in Huntington disease.
    Arch Neurol (2008) 65, 482-488.
    Arnulf, I., Nielsen, J., Lohmann, E., Schiefer, J., Wild, E., Jennum, P., Konofal, E., Walker, M., Oudiette, D., Tabrizi, S. and Durr, A.
  66. Huntington’s disease phenocopy syndromes.
    Curr Opin Neurol (2007) 20, 681-687.
    Wild, E. J. and Tabrizi, S. J.
  67. The differential diagnosis of chorea.
    Pract Neurol (2007) 7, 360-373.
    Wild, E. J. and Tabrizi, S. J.
  68. Plasma neurofilament heavy chain levels in Huntington’s disease.
    Neurosci Lett (2007) 417, 231-233.
    Wild, E. J., Petzold, A., Keir, G. and Tabrizi, S. J.
  69. Analysis of potential transcriptomic biomarkers for Huntington’s disease in peripheral blood.
    Proc Natl Acad Sci U S A (2007) 104, 14424-14429.
    Runne, H., Kuhn, A., Wild, E. J., Pratyaksha, W., Kristiansen, M., Isaacs, J. D., Regulier, E., Delorenzi, M., Tabrizi, S. J. and Luthi-Carter, R.
  70. Proteomic profiling of plasma in Huntington’s disease reveals neuroinflammatory activation and biomarker candidates.
    J Proteome Res (2007) 6, 2833-2840.
    Dalrymple, A., Wild, E. J., Joubert, R., Sathasivam, K., Bjorkqvist, M., Petersen, A., Jackson, G. S., Isaacs, J. D., Kristiansen, M., Bates, G. P., Leavitt, B. R., Keir, G., Ward, M. and Tabrizi, S. J.
  71. Vasculitic presentation of staphylococcal meningitis.
    Arch Neurol (2007) 64, 1788-1789.
    Bentley, P., Qadri, F., Wild, E. J., Hirsch, N. P. and Howard, R. S.
  72. Predict-HD and the future of therapeutic trials.
    Lancet Neurol (2006) 5, 724-725.
    Wild, E. J. and Tabrizi, S. J.
  73. Deja vu in neurology.
    J Neurol (2005) 252, 1-7.
    Wild, E.
  74. Thyrotoxic periodic paralysis in a Maori patient.
    N Z Med J (2004) 117, U1204.
    Wild, E.